Jeffrey M. Leiden

2019 - Vertex Pharmaceuticals

In 2019, Jeffrey M. Leiden earned a total compensation of $18.8M as Executive Chairman at Vertex Pharmaceuticals, which was about the same as previous year.

Compensation breakdown

Non-Equity Incentive Plan$3,510,000
Option Awards$4,572,039
Salary$1,300,000
Stock Awards$9,334,681
Other$73,265
Total$18,789,985

Leiden received $9.3M in stock awards, accounting for 50% of the total pay in 2019.

Leiden also received $3.5M in non-equity incentive plan, $4.6M in option awards, $1.3M in salary and $73.3K in other compensation.

Rankings

In 2019, Jeffrey M. Leiden's compensation ranked 188th out of 13,971 executives tracked by ExecPay. In other words, Leiden earned more than 98.7% of executives.

ClassificationRankingPercentile
All
188
out of 13,971
99th
Division
Manufacturing
67
out of 5,692
99th
Major group
Chemicals And Allied Products
18
out of 2,189
99th
Industry group
Drugs
14
out of 1,875
99th
Industry
Pharmaceutical Preparations
13
out of 1,387
99th
Source: SEC filing on April 28, 2020.

Leiden's colleagues

We found six more compensation records of executives who worked with Jeffrey M. Leiden at Vertex Pharmaceuticals in 2019.

2019

Stuart Arbuckle

Vertex Pharmaceuticals

EVP & Chief Commercial Officer

2019

Reshma Kewalramani

Vertex Pharmaceuticals

Chief Executive Officer

2019

Amit Sachdev

Vertex Pharmaceuticals

EVP & Chief Patient Officer

2019

Charles Wagner

Vertex Pharmaceuticals

Chief Financial Officer

2019

Paul Silva

Vertex Pharmaceuticals

SVP & Corporate Controller

2019

Ian Smith

Vertex Pharmaceuticals

Chief Financial Officer

News

You may also like